Search - tctmd.com

Displaying 21 - 40 of 519

Sort: Relevancy | Date

Flash Debate: Counterpoint – 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Presentation TCT 2016

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Trial #2 - The Essentials of ... the MATRIX Trial – Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Presentation TCT 2016

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Presenter: Sunil V. Rao, Harvey D. White, Salvatore Brugaletta

October 31, 2016

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Presentation TCT 2016

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Presenter: John M. Lasala, Philippe Pibarot, Jürgen Rothe

October 31, 2016

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

Presentation TCT 2016

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

Presenter: Neal S. Kleiman, David F. Kong, Didier Carrié

October 31, 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No – Chronic Anticoagulation Should be Offered First

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

October 29, 2016

News Daily News

Short Bouts of Atrial Tachyarrhythmia Do Not Worsen Prognosis, Study Suggests

October 19, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

October 18, 2016

News Daily News

A-fib Screening With Smartphone-Based ECG Feasible, but Clinical Impact Unclear

October 13, 2016

News Daily News

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Michael O'Riordan

October 11, 2016

News Daily News

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

October 07, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

欧洲大型分析显示当前 NSAID 使用与心力衰竭的风险增加相关

Michael O'Riordan

September 30, 2016

News Daily News

Low-Dose NOACs Top Warfarin in Asian Patients in Everyday Practice, Retrospective Study Suggests

September 26, 2016

News Conference News PCR London Valves 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

September 20, 2016

News Daily News

Bivalirudin? Heparin? Physicians Are Divided Over Antithrombotic Choices for PCI in STEMI, Survey Shows

Yael L. Maxwell

September 15, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

September 13, 2016

News Conference News ESC 2016

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

September 02, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.